Calypte und die Zeit nach AIDS2004 in Bangkok

Gruß

C.O  

Cholestech Names Barbara McAleer to Position of Vice President of Quality and Regulatory Affairs
2/2/2005 6:30:11 AM



HAYWARD, Calif., Feb 02, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cholestech Corporation (CTEC) today announced that Barbara McAleer has joined Cholestech as Vice President of Quality and Regulatory Affairs. Ms. McAleer brings to Cholestech over 20 years of experience in the healthcare industry, recognized for her success in the areas of quality, operations, compliance and management.


"Cholestech is committed to providing all our customers high quality product that they can rely on. Bringing the quality function to the executive level is further evidence of that commitment," said Warren E. Pinckert II, president and chief executive officer of Cholestech. "Barb brings to Cholestech significant experience in building world-class quality organizations. I look forward to working with her as we continue our focus on quality and customer service."

Ms. McAleer has been working as a managing partner at LOL Partners, a consulting firm specializing in the healthcare industry. Previously, Barb was Vice President of Operations and Quality for Calypte Biomedical Corporation, a manufacturer of HIV diagnostic kits. Previous to that position, she was the General Manager of Calypte's Rockville, Maryland operations. While at Calypte, Ms. McAleer was credited with significantly improving overall product margin through process improvements and cost savings.

Before joining Calypte, Ms. McAleer spent 18 years with Johnson & Johnson, starting out first in their Ethicon unit in positions within its manufacturing area, moving to the quality assurance area within Vistakon and ultimately becoming its Director of Quality Assurance. Following Vistakon, Ms. McAleer moved to the Lifescan division first as the Senior Director and then Vice President of Quality Assurance, where she redesigned Lifescan's quality systems to significantly improve compliance status.

Cholestech intends to grant Ms. McAleer a non-qualified stock option to purchase up to 40,000 shares of its common stock, pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv). The option's exercise price will be set at the next board meeting and will be equal the closing price of the Company's stock on The NASDAQ Stock Market on the day of the board meeting. It will have a seven-year term and vest monthly over four years, subject to continued employment with the Company.

About Cholestech

Cholestech is committed to enabling people to lead longer, healthier and more active lives. Cholestech provides easy to use, accessible diagnostic tools and information to health care practitioners in over 35 countries around the world. Cholestech offers efficient and economic diagnostic testing for cholesterol and related lipids, blood glucose and glycemic control, and liver function at the point of care. Health care providers can use the CLIA-waived Cholestech LDX(R) and GDX(TM) Systems to initiate and monitor the progress of patient therapy. By providing effective disease management solutions, Cholestech's goal is to be a leading provider of diagnostic tools and information for immediate risk assessment and therapeutic monitoring of heart disease and diabetes.

Cholestech LDX(R) is a registered trademark and Cholestech GDX(TM) is a trademark of Cholestech Corporation. All other trademarks mentioned in this document are the property of their respective owners. For more information about Cholestech and its products visit us on the web at .cholestech. com.

SOURCE Cholestech Corporation

Warren E. Pinckert II, President and Chief E



Gruß

C.O
 

Gruß

C.O  

 

abwartende Haltung...


Gruß

C.O  

ere dinge. primacom z.b ;O) mein durchschnitt liegt derzeit bei 1,58 ;O)  

Ich bin die Tage fixiert auf Caly..

Gruß

C.O  

 

 

Gruß

C.O  

ich glaube wir sind so die einzigen die hier treu geblieben sind ..

Unser warten wird sich belohnen vertraue mir ; )

Gruß

C.O  

 

 

Hab leider gerade wenig Zeit... Aber läuft doch !  

werden gut werden, aber es wird nichts verkauft werden, weil die zulassungen immer noch fehlen.

nutzt einen anstieg auf ev. 0,40$ zum endgültigen ausstieg!  

läuft Kade läuft und es wird noch besser laufen..


Gruß

C.O  

 

Reanimation nennt man das in der modernen Medizin ;-)

Und nu, was sagst zum heutigen Kursverlauf ? Schnellstmöglich aussteigen, oder ?!

;-)  

After Hours
Last: $0.35  

After Hours
High: $0.35  

von gestern USA:

bid = 416,000
ask =1,122,800
-------------------------
total =1,538,800


Die meisten Trades kamen aus dem ASK ;-)
 

HIV: Volume Spike; 46% > 20-adsv, Stock +17.24%

Wednesday, February 02, 2005 14:00 ET

This is the 1st VOLUME alert for HIV in the past 7 calendar days.

Trading for Calypte Biomedical Corporation (AMEX: HIV) has been heavier than usual in today's session. By 14:00 ET, the stock had already traded 1,029,900 shares via 68 trades. The cumulative volume is 45.86% above its 20-day average of 706,065. Normally the stock experiences around 59 individual trades per session.

So far, today's volume surge has caused a net rise in HIV's stock price. At the time of this alert, the stock was trading at $0.340, up $0.050 (+17.24%).

One year ago, the Company's shares closed at $0.660. The price has declined more than 48 percent since then.

Over the last 10 trading session HIV has traded in a range between $0.260 and $0.300 and is currently trading 54.36% below its 52-week high of $0.745 set on July 09,2004 and 88.89% above its 52-week low of $0.180 from November 16,2004.

In the previous 3 sessions, HIV trading has displayed a mixed trend. Closing results have been as follows:

February 01, 2005 --- closed at $0.290 up $0.010 (+3.57%) on 464,700 shares
January 31, 2005 --- closed at $0.280 even for the day on 669,100 shares
January 28, 2005 --- closed at $0.280 down $0.010 (-3.45%) on 175,900 shares

The Company last released news on January 18, 2005:

"Calypte Biomedical Issues $2 Million Note"

CALYPTE BIOMEDICAL CORPORATION
Calypte Biomedical Corporation is a health care company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Imnunodeficiency Virus Type 1, sexually transmitted diseases and other chronic illnesses. The Company's tests include the screening enzyme immunoassay (EIA) and supplemental Western Blot tests, the only two FDA-licensed HIV-1 antibody tests that can be used on urine samples.

 

dann aber raus, es wird nichts verkauft....und die zulassungen?

ioch würde sogar vor den testergebnissen noch aussteigen...  

du gar keine hast, du Oberschlauer Augridjünger .
IFEX hast du ja wieder empfohlen lach klasse Kursverlauf muhahahahaha  

;-)  

Gruß

C.O